Mirum acquires Bluejay Therapeutics

Mirum Pharmaceuticals has finalized its acquisition of Bluejay Therapeutics, enhancing its portfolio with brelovitug, a promising treatment for chronic hepatitis delta virus (HDV). The deal underscores Mirum's focus on rare diseases, particularly rare liver conditions, where it aims to leverage its global development and commercial competencies to address significant unmet medical needs.

The acquisition grants Mirum global rights to brelovitug, a late-stage monoclonal antibody currently under evaluation in the AZURE Phase 3 clinical program. This agent is notable for its FDA Breakthrough Therapy and European Medicines Agency's PRIME designations, positioning it as a potential first-in-class therapy for HDV, a severe liver condition with no approved treatments in the United States. Topline results from this pivotal trial are anticipated in the latter half of 2026, with possible regulatory submissions and market debuts projected for 2027.

Chris Peetz, CEO of Mirum Pharmaceuticals, emphasized the strategic alignment of this acquisition with the company's expertise in rare liver diseases. The integration of Bluejay's team and pipeline is set to bolster Mirum's capabilities as it edges closer to commercialization milestones for brelovitug. The antibody targets HDV by neutralizing the virus and its hepatitis B virus (HBV) counterpart, both of which share an antigen that brelovitug effectively binds and neutralizes, potentially offering a significant therapeutic benefit.

Financially, the acquisition involved a cash and stock combination, supplemented by potential sales-based milestone payments. To facilitate the integration and advance brelovitug's development, Mirum secured approximately $268.5 million through private placement financings. These funds are earmarked for continued clinical development and commercialization efforts, as well as the exploration of Bluejay's other investigational assets.

In the broader market context, Mirum's expansion into HDV treatment underscores a strategic push into an under-addressed segment of the biotechnology sector. Competing companies may now face increased pressure to accelerate their own developmental pipelines or form strategic partnerships to remain competitive. This acquisition and the ensuing development activities could significantly reshape the landscape of rare disease therapeutics, particularly in addressing the unmet needs of the HDV patient population.

With the acquisition complete, Mirum's focus will be on executing the AZURE Phase 3 trials and preparing for potential regulatory filings. The biopharmaceutical industry will be closely watching the outcomes of these efforts and the subsequent regulatory review process, given the high stakes involved in pioneering a new treatment for a challenging and severe medical condition.